Apazoglou, Kallia
Farley, Séverine
Gorgievski, Victor
Belzeaux, Raoul
Lopez, Juan Pablo
Grenier, Julien
Ibrahim, El Chérif
El Khoury, Marie-Anne
Tse, Yiu C.
Mongredien, Raphaele
Barbé, Alexandre
de Macedo, Carlos E. A.
Jaworski, Wojciech
Bochereau, Ariane
Orrico, Alejandro
Isingrini, Elsa
Guinaudie, Chloé
Mikasova, Lenka
Louis, Franck
Gautron, Sophie
Groc, Laurent
Massaad, Charbel
Yildirim, Ferah
Vialou, Vincent
Dumas, Sylvie
Marti, Fabio http://orcid.org/0000-0002-3604-457X
Mechawar, Naguib
Morice, Elise
Wong, Tak P. http://orcid.org/0000-0001-8611-4911
Caboche, Jocelyne
Turecki, Gustavo
Giros, Bruno http://orcid.org/0000-0001-5876-9822
Tzavara, Eleni T.
Article History
Received: 26 September 2016
Accepted: 12 February 2018
First Online: 7 May 2018
Competing interests
: The TDE peptide used in the present article and its application in depression are protected by the published patents WO 2006/087242 and WO2010/037841, respectively, filed in Europe, the United States, Canada and Japan. This does not alter our adherence to Nature Publishing Group policies on sharing data and materials. J.C., B.G. and E.T.T. are founding shareholders of Melkin Pharmaceuticals, a biotech company, which has developed the TDE peptide as a drug candidate. The company did not have any role in study design, data collection and analysis, decision to publish or preparation of the manuscript.